Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02047604 · ClinicalTrials.gov registry record · Phase 2
(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis
A Phase 2 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT02047604 is a Phase 2 study that has completed, run by Bausch Health Americas. The registered enrollment target is 41 participants.
The verdict
NCT02047604, a Phase 2 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
Interventions
- DRUG SAN-300 0.5 mg/kg QW
- DRUG SAN-300 1.0 mg/kg QW
- DRUG SAN-300 2.0 mg/kg QOW
- DRUG SAN-300 4.0 mg/kg QOW
- DRUG SAN-300 4.0 mg/kg QW
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-03-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02047604
The ClinicalTrials.gov registry entry for NCT02047604 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which SAN-300 0.5 mg/kg QW is the first listed.
NCT02047604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02047604 about?
NCT02047604 is a clinical study titled "(C2013-0302) Safety and Efficacy of Escalating Doses of SAN-300 in Patients With Rheumatoid Arthritis". A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients with Active Rheumatoid Arthritis with Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
What is the current status of trial NCT02047604?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2013-12. Estimated completion is 2017-03-23.
What interventions are being tested in trial NCT02047604?
The interventions under investigation include: SAN-300 0.5 mg/kg QW (DRUG), SAN-300 1.0 mg/kg QW (DRUG), SAN-300 2.0 mg/kg QOW (DRUG), SAN-300 4.0 mg/kg QOW (DRUG), SAN-300 4.0 mg/kg QW (DRUG).
Who is sponsoring clinical trial NCT02047604?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.